Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in Giant Cell Arteritis
NCT03600805Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of sarilumab in giant cell arteritis (GCA) (4 arms), sponsored by Sanofi. Primary endpoints: Proportion of Participants Who Achieved Sustained Disease Remission at Week 52 and Proportion of Participants Who Achieved Sustained Disease Remission at Week 24. Started Nov 2018; status: terminated.
02
Drugs
sarilumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03600805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600805.